160 results about "Mental illness" patented technology

The present invention provides methods and systems or apparatuses, to analyze multiple molecular and clinical variables from an individual diagnosed with a psychiatric disorder, such as post-traumatic stress disorder (PTSD), in order to optimize medication selection for therapeutic response. Molecular co-variables include polymorphisms in genes including those involved in central control and mediation of the hypothalamic-pituitary axis (HPA) stress response, the density of methylation in regulatory regions of said polymorphic genes, polymorphisms in genes that encode cytochrome P450 enzymes responsible for drug metabolism, and drug-drug and drug-gene interactions. Clinical co-variables include but are not limited to the sex, age and ethnicity of that individual, medication history, family history, diagnostic codes, Pittsburgh insomnia rating score, and Charlson index score. The system makes a determination based on unstructured and structured data types derived from internal and external knowledge resources to determine psychotropic drug choice that best matches the molecular and clinical variation profile of an individual patient. The decision support system provides a therapeutic recommendation for a clinician based on the patient's variation profile.

A medical digital expert system to predict a patient's response to a variety of treatments (using pre-treatment information) is described. The system utilizes data fusion, advanced signal / information processing and machine learning / inference methodologies and technologies to integrate and explore diverse sets of attributes, parameters and information that are available to select the optimal treatment choice for an individual or for a subset of individuals suffering from any illness or disease including psychiatric, mental or neurological disorders and illnesses. The methodology and system can also be used to determine or confirm medical diagnosis, estimate the level, index, severity or critical medical parameters of the illness or condition, or provide a list of likely diagnoses for an individual suffering / experiencing any illness, disorder or condition.

Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.

The present invention is a system and method of related healthcare processes protecting workplace productivity and mental health. It provides tools to patients and their physicians to assist them in identifying, managing and tracking mental health disorders. It also provides information to employers and health and disability insurers regarding the most effective interventions promoting productivity and mental and physical health. Through an interactive process with a website, the patient undergoes an initial screening for the presence of a mental health disorder, in an anonymous and confidential manner. After the first stage of screening, if the possibility of a mental disorder is identified, questions will be posed to the patient to determine the level of risk for possible diagnosis of a mental disorder by the M.D. A printable diagnostic risk map is provided in addition to appropriate care maps and follow up maps that guide physician and patient management of these disorders. Compliance with current best practices in disease management by both patient and physician is supported by scientific information at the lay level and physician level. Clinical and functional outcomes are quantified economically. Outcomes are tracked individually, but only aggregate information is provided to the employer and / or insurer. The overall result is improved mental health, physical health, productivity for large populations in a cost effective manner without requiring changes to the existing health care systems

The invention discloses a pure Chinese medicinal preparation for treating mental illness, which is prepared from Chinese angelica, szechuan lovage rhizome, peach seed, Chinese thorowax root, radix curcumae, beautiful sweetgum fruit, fructus citri immaturus exsiccatus, dwarf lilyturf tuber, costustoot, nutgrass galingale rhizome, wrinkled gianthyssop herb, flos chrysanthemi, dried orange peel, pinellia tuber, cortex magnoliae officinalis, areca seed, oriental waterplantain rhizome, liquorice root, Chinese ligusticum rhizome and semen trichosanthis in a certain weight ratio. The medicament of the invention can be prepared into any common oral administration formulation. In a prescription of the invention, the medicaments have the excellent synergistic effect on the curative effect through reasonable compatibility; channels and collaterals are dredged through liver rejuvenation, vigoration of blood circulation, promotion of qi circulation, xeransis, phlegm elimination and melancholy dispelling, and the circulation of qi and blood all over the bodies of patients is regulated, so that the qi, blood and body fluid are evacuated normally, and viscus organs are promoted to perform normal physiological activity; and therefore, the viscus function operates normally and diseases are cured. Compared with the prior art, the pure Chinese medicinal preparation has the advantages of quick response, high cure rate, relapse prevention, no toxic or side effect and easy acceptance by the patients.

The present application relates to the use of SNPs and differential exon expression to characterize, diagnose or treat bipolar disorder and other mental illnesses, such as major depressive disorder and schizophrenia.

Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.